Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients

Treatment tested

• Metformin
• Interferon beta-1a

  Interferon alpha/beta receptor agonist

Other measures (5)

Inclusion Criteria: * Age between 18 and 50 years at time of signing informed consent form. * Relapsing- remitting multiple sclerosis as per the McDonald 2017 criteria, including an MRI brain satisfying the 2017 radiological criteria. * Full-field visual evoked potential (VEP) P100 latency in at least one eye of ≥118 ms. * Kurtzke EDSS step 0.0 - 6.0. * At the time of screening, being treated with a stable dose for at least 6 months of a category 1 multiple sclerosis DMT or for at least 2 years with a category 2 DMT. Exclusion Criteria: * People taking medication for Diabetes Mellitus at screening. * Female participants who are pregnant, lactating, planning pregnancy, or unwilling to use reliable contraception during the trial. * Significant liver impairment; alanine aminotransferase > 3 times the upper limit of normal. * People suffering from congestive heart failure, chronic lung disease with hypoxia, and severe anemia. * Patients with compromised renal function ((eGFR \<60 mL/min/1.73m2) or coexistent hypoxic conditions should not be given metformin. * Chronic or acute intake of large amounts of alcohol may potentiate the effect of metformin on lactate metabolism. * Patients had been prescribed oral, intravenous, and intramuscular corticosteroids for one month prior to study.

This study aims to evaluate the effect of Metformin as add- on therapy for improving the outcome in RRMS patients.